The Role of Posterior Tibial Slope in Range of Motion After Total Knee Arthroplasty for Haemophilia Patients: A Retrospective Study [0.03%]
血友病患者全膝关节置换术后后胫骨斜坡在活动范围中的作用：回顾性研究
Shineng Lin,Haojing Zhou,Zhaokai Jin et al.
Shineng Lin et al.
Introduction: Patients with haemophilia typically achieve only approximately a 90° range of motion (ROM) following total knee arthroplasty (TKA), which still significantly affects their daily life. ...
HAEMFIX: Impact of Switching From SHL-FIX to EHL-FIX in Patients With Haemophilia B [0.03%]
HAEMFIX：与甲型血友病患者从SHL-FIX切换至EHL-FIX的影响关系研究
Jasmin Lonardi,Susan Halimeh,Sylvia von Mackensen et al.
Jasmin Lonardi et al.
Introduction: Haemophilia B is an X-linked recessive bleeding disorder caused by coagulation factor IX (FIX) deficiency. Treatment involves intravenous replacement of FIX. Recently, extended half-life (EHL) FIX products h...
Predominance of Radiographical Femoral Component Loosening Signs in Total Knee Arthroplasty for Hemophilic Arthropathy [0.03%]
血友病关节病膝关节置换术中股骨组件影像学松动的高发生率
Başak Koç,Bülent Zülfikar,Ufuk Arzu et al.
Başak Koç et al.
Aim: To compare the frequency and timing of femoral- versus tibial-sided radiographic radiolucencies after posterior-stabilized TKA in people with haemophilia (PwH) versus non-haemophilic controls. ...
The WFH Guidelines for the Management of Haemophilia: AAV Gene Therapy, 2025 [0.03%]
在家工作的指南：血友病AAV基因治疗管理（2025年版）
Glenn F Pierce,Margareth C Ozelo,Johnny Mahlangu et al.
Glenn F Pierce et al.
Supporting Patient-Centred Decisions on Gene Therapy for Haemophilia A: A Conceptual Model [0.03%]
一种概念模型：支持以患者为中心的A型血友病基因治疗决策
Giovanni Di Minno,Sarah Bigi,Serena Barello et al.
Giovanni Di Minno et al.
Burden of Care and Quality of Life Among Caregivers of Filipino Children With Haemophilia Before and During the COVID-19 Pandemic: A Cross-Sectional Study [0.03%]
菲律宾血友病儿童照料者的负担和生活质量：新冠疫情前后照料者的生活质量横断面研究
Noah S Sacluti,Flerida G Hernandez
Noah S Sacluti
Introduction: The pandemic affected the quality of life (QoL) of children with haemophilia, nevertheless their caregivers. The disease burden to caregivers and its influence on well-being may become a determinant of the q...
Canadian Clinical Experience on Switching From Standard Half-life Recombinant Factor VIII (rFVIII), Octocog Alfa, to Extended Half-life rFVIII, Damoctocog Alfa Pegol, in Persons With Haemophilia A ≥ 12 Years Followed in a Comprehensive Haemophilia Care Program in Canada [0.03%]
加拿大血友病综合护理项目中关于从常规半衰期重组VIII因子(FVIII)凝血酶原复合物浓缩剂转换为延长半衰期FVIII的临床经验：一项针对≥12岁A型血友病患者的队列研究
Davide Matino,Anthony K C Chan,Kay Decker et al.
Davide Matino et al.
This is a plain language summary on switching from the medicine octocog alfa to a new medicine damoctocog alfa pegol (BAY 94-9027, Jivi) for the treatment of haemophilia A in Canada. ...
Management of von Willebrand Disease With a Factor VIII-Poor von Willebrand Factor Concentrate: Results From the Paediatric Cohort of a Prospective Observational Post-Marketing Study [0.03%]
一种低FVIII活性的vWF浓缩物治疗血管性血友病的研究——一项上市后观察研究的儿童队列结果
Jenny Goudemand,Annie Borel-Derlon,Ségolène Claeyssens et al.
Jenny Goudemand et al.
Introduction: Although clinical experience of a triple-secured, plasma-derived, von Willebrand factor (pdVWF), almost devoid of Factor VIII (FVIII) in adults with von Willebrand disease (VWD), is widely reported, its use ...